Role of finasteride in the treatment of recurrent hematuria secondary to benign prostatic hyperplasia
โ Scribed by Carlin, Bruce I.; Bodner, Donald R.; Spirnak, J. Patrick; Resnick, Martin I.
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 380 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0270-4137
No coin nor oath required. For personal study only.
โฆ Synopsis
Objectives:
We evaluated the efficacy of finasteride for the treatment of gross hematuria secondary to benign prostatic hyperplasia in a prospective fashion.
Methods:
Twelve patients with recurrent episodes of gross hematuria secondary to benign prostatic hyperplasia were treated with finasteride 5 mg/day. before initiating treatment, we excluded other sources of hematuria using intravenous urography, cystoscopy, and urine culture.
Results:
Bleeding subsided within 2 weeks of treatment in all 12 patients. minimum follow-up was 6 months. finasteride was well tolerated by all 12 patients.
Conclusions:
Finasteride appears to be effective in treating recurrent gross hematuria secondary to benign prostatic hyperplasia. this therapy should be considered an alternative to transurethral resection of the prostate or hormonal ablation in patients with recurrent hematuria and no significant obstructive uropathy or adenocarcinoma of the prostate.
๐ SIMILAR VOLUMES
BACKGROUND. This study examined the impact of secondary cytoreductive surgery on survival of patients with recurrent epithelial ovarian carcinoma. ## METHODS. One hundred six patients with a disease free interval (DFI) ฯพ 6 months after primary treatment underwent secondary cytoreductive surgery. M
T1, 2, 3pN0, M0), 44 patients with BPH, and 54 healthy Charite ยด, Humboldt University Berlin, Berlin, Gercontrols. Prostate volume was determined by transrectal ultrasound. many. ## RESULTS. The median values of t-PSA and f-PSA% were 7.8 mg/L and 10.5% in PCa patients, 4.3 mg/L and 20.8% in patie
## Background: The n-hexane lipido-sterol extract of serenoa repens (lsesr, permixon, pierre fabre medicament, castres, france), a phytotherapeutic agent used in the treatment of benign prostatic hyperplasia (bph), has a multisite mechanism of action including inhibition of types 1 and 2 5alpha-red